# Evolution Agent Output

Cycle ID: 2  
Role: Refine, merge, simplify, and strengthen the strongest candidate‑axis validation hypotheses while removing unsupported claims, eliminating redundancy, and enforcing the evidence‑availability boundaries documented by the Tool Use Agent and Meta‑review.

---

## Actions taken

1. **Merged** all AMD1‑immune hypotheses from generation_metabolic (Axis1_AMD1_immune), generation_3 (Axis1_AMD1_immune), and similar immune‑mediated variants into a single **refined Axis1_AMD1_immune**. Removed premature TGF‑β1/EV/specific‑cytokine commitments.
2. **Refined** the AMD1‑direct‑vascular hypothesis (Axis2_AMD1_vascular) by combining generation_metabolic’s version with the stronger spatial‑validation demands from reflection agents; kept it as a secondary hypothesis.
3. **Merged** all inosine‑adenosine‑immune hypotheses (generation_metabolic Axis4_Inosine_immune, generation_2 Axis2_Pnp_Immune, generation_3 Axis2_Pnp_immune) into **refined Axis1_Inosine_immune**.
4. **Refined** the inosine‑adenosine direct‑vascular hypothesis (Axis2_Inosine_vascular) from generation_metabolic and generation_2, sharply downgrading its strength and noting its dependency on unrealized isotopic‑tracing evidence.
5. **Rejected/removed** the following because they lack required data anchors or are unsupported:
   - AMD1‑EV/stromal (Axis3_AMD1_EV) – EV‑biogenesis gene expression not verified; spec. polyamine‑EV loading unsubstantiated.
   - Inosine‑stromal activation – no tissue‑level adenosine/fibroblast data; EV version equally speculative.
   - AMD1‑thrombo‑inflammatory – depends on unverified F3/Thbs1 expression and an eIF5A‑hypusination chain not demonstrated in MKs.
   - Revived MK matricellular/coagulation/EV secretome – no independent Seurat data; not anchored to a metabolite‑enzyme chain; excluded until mandatory queries are completed and reported by the Tool Use Agent.

**Result:** Four refined hypotheses, all anchored to Evo_H1 or Evo_H2, meeting the requirement that at least 4 originate from the metabolic shortlist. No new broad mechanism class is introduced. All downstream commitments are explicitly labelled as provisional.

---

## Refined hypotheses

---

### Hypothesis ID: Axis1_AMD1_immune  
**Original hypothesis IDs merged:** generation_metabolic‑Axis1_AMD1_immune, generation_3‑Axis1_AMD1_immune, plus parts of generation_1‑Axis1_AMD1_TGFB1_EV (immune/TGF‑β candidate components removed).  
**Revision type:** merge and refine  
**PI feedback addressed:** Keep Evo_H1 direction; generate candidate‑axis validation hypotheses; avoid over‑resolving downstream mediators; use mandatory Seurat and public‑data context.  
**Revised hypothesis title:**  
MK‑AMD1‑polyamine axis shifts the perivascular immune environment to promote pulmonary vascular muscularization.

**Revised core directional hypothesis:**  
Hypoxic upregulation of AMD1 in lung‑resident MKs enhances polyamine production (spermidine/spermine), which acts on perivascular immune cells to create a pro‑remodeling tone (candidate example: altered T‑cell/macrophage activation), thereby driving PASMC hyperplasia and medial thickening.

**Revised direction‑level reasoning summary:**  

- **Data anchor:**  
  Methionine elevated in PH‑CD41⁺ MKs (log2FC 3.26, sFig6A); *Amd1* is MK‑enriched (log2 enrichment 1.35, 31.4% MK⁺ vs 14.9% other) and significantly upregulated in PH MKs (log2FC 1.77, p = 6.55 × 10⁻⁶, Wilcoxon, Seurat).  

- **Biological interpretation:**  
  Methionine accumulation with parallel AMD1 induction suggests increased S‑adenosylmethionine (SAM) flux into the polyamine synthesis branch – a hypoxia‑responsive metabolic switch that drives spermidine/spermine production.  

- **MK‑linked pathway logic:**  
  AMD1 is the rate‑limiting enzyme that decarboxylates SAM to feed polyamine synthesis. Elevated AMD1 in hypoxic MKs is expected to raise intracellular polyamine pools, which can be exported or released (as free molecules, within EVs, or upon MK lysis) into the perivascular niche.  

- **Candidate downstream axis:**  
  **Immune‑mediated** – polyamines can influence T‑helper/Th17‑like balance and macrophage polarization, thereby creating a pro‑remodeling perivascular milieu. Direct vascular‑wall and EV/stromal are alternative, less‑supported routes that remain plausible.  

- **Remodeling logic:**  
  Immune‑derived signals promote PASMC proliferation and vessel wall muscularization, characteristic of hypoxia‑induced PH.  

- **Key uncertainty:**  
  Whether MK‑derived polyamines reach perivascular immune cells at immunomodulatory concentrations, which immune cell subset(s) mediate the effect, and whether the net outcome is indeed pro‑remodeling.

**Revised directional chain:**  

1. Hypoxia → lung‑resident MKs upregulate *Amd1*, boosting polyamine (spermidine/spermine) production.  
2. Polyamines are exported/released into the perivascular space.  
3. Broad downstream axis: **Immune‑mediated** – polyamines act as intercellular signals on perivascular T‑cells and macrophages, shifting their activation state (candidate examples: enhanced Th17‑like responses, alternative macrophage activation).  
4. Altered immune tone sustains smooth muscle cell hyperplasia and suppresses vascular repair.  
5. Contributes to muscularization and vascular stiffening.

**Candidate downstream axes:**  

- *Plausible axes:* Immune‑mediated, direct vascular‑wall (polyamines as PASMC mitogens), EV/stromal (polyamine‑loaded EVs acting on fibroblasts), unresolved.  
- *Working model (provisional):* Polyamine‑driven skewing of perivascular T‑cell/Th17‑like tone, with macrophage involvement as a complementary pathway.  
- *Specific examples (candidate only):* Spermidine may suppress Treg function or enhance IL‑17‑producing cells; polyamines can promote a pro‑fibrotic macrophage phenotype. None are settled.  
- *What remains unresolved:* The identity of the dominant immune effector subset, polyamine receptor(s) involved, and whether the effect is mediated by free polyamines or EV‑packaged cargo.

**Evidence retained:**  

- *User‑provided data:* Methionine elevation in PH MKs; *Amd1* MK enrichment and PH‑up differential expression.  
- *Public data:* GSE289322 analysis files exist but results not yet displayed; if GSEA for arginine/proline metabolism or cysteine/methionine metabolism shows enrichment (FDR < 0.25), it would strengthen tissue‑level propagation of MK metabolic shifts – **currently not visible**.  
- *Literature:* AMD1‑polyamine axis influences immune cell differentiation in cancer models; no direct PH‑MK studies.  

**Unsupported claims removed:**  

- Removed any implication that TGF‑β1 or PDGF‑BB are the primary downstream mediators (they remain candidate examples only if independently supported).  
- Removed EV‑TGF‑β1 loading as a required step; the axis is now purely paracrine/soluble.  
- Deleted references to specific T‑helper subsets (Th17) or cytokines (IL‑17) except as explicitly provisional examples.  

**Evidence added:** *(none from new public‑data analysis, as the results remain unavailable)*  

**Improved experimental validation:**  

- *Perturbation:* Conditional *Amd1* knockout in MK/platelet lineage (Pf4‑Cre; *Amd1*^fl/fl).  
- *Model:* Chronic hypoxia (3 wk) in mice.  
- *Readout:* Flow‑cytometric profiling of lung perivascular immune cells (CD4⁺ T‑cell subsets, macrophage polarization markers), multiplex cytokine array on lung homogenate, spermidine/spermine concentration in microdissected perivascular tissue (LC‑MS), and medial thickness/α‑SMA muscularization.  
- *Control:* Littermate WT and cre‑negative controls. Pharmacological polyamine synthesis blockade (e.g., DFMO) in parallel WT mice as an orthogonal test.  
- *Expected result:* *Amd1*‑KO reduces perivascular polyamine levels, alters immune cell activation (e.g., fewer pro‑remodeling phenotypes), and attenuates muscularization.  
- *Falsifying result:* No change in perivascular immune composition or cytokine profile despite confirmed reduction in polyamines; OR polyamine blockade fails to reverse immune‑mediated remodeling. In that case, the immune axis is not dominant.

**Remaining weaknesses:**  

- Spermidine/spermine have not been measured in MKs or lung tissue; the chain rests on the inferred flux through AMD1.  
- CD73 or ecto‑nucleotidase expression on MKs/perivascular cells not investigated (not relevant here, but noted for completeness).  
- Mandatory Seurat expression for the extended gene list has only been self‑reported by generation agents, not verified by Tool Use Agent; however, this hypothesis does not depend on those genes.  

**Recommendation:**  
- **Ready for PI review** as the top Evo_H1 immune candidate; advance only after direct polyamine quantification and spatial validation.

---

### Hypothesis ID: Axis2_AMD1_vascular  
**Original hypothesis IDs merged:** generation_metabolic‑Axis2_AMD1_vascular, generation_2‑Axis2_AMD1_vascular (if present), with input from reflection critiques.  
**Revision type:** refine  
**PI feedback addressed:** Keep direct vascular‑wall route as a secondary candidate axis; incorporate spatial and mitogenicity evidence requirements.  
**Revised hypothesis title:**  
MK‑AMD1‑derived polyamines act as paracrine mitogens on pulmonary arterial smooth muscle cells.

**Revised core directional hypothesis:**  
AMD1‑driven polyamine production in hypoxic lung MKs, if the MKs reside in immediate proximity to the vessel media, can directly stimulate PASMC proliferation through candidate mechanisms such as eIF5A hypusination or polyamine‑sensing receptors, leading to medial thickening.

**Revised direction‑level reasoning summary:**  

- *Data anchor:* Same methionine‑AMD1 axis as above.  
- *Biological interpretation:* Polyamines are established growth‑promoting factors for smooth muscle cells; if MKs are positioned near the medial layer, they could serve as a local polyamine source.  
- *MK‑linked pathway logic:* AMD1 commits SAM‑derived carbon to spermidine/spermine synthesis; these polyamines, once exported, can be taken up by PASMCs via polyamine transporters and drive cell cycle progression.  
- *Candidate downstream axis:* **Direct vascular‑wall**. Immune‑mediated and EV/stromal are alternative routes that may operate in parallel.  
- *Remodeling logic:* PASMC hyperplasia → medial hypertrophy → increased vascular resistance.  
- *Key uncertainty:* The spatial relationship between lung MKs and the arterial media, the effective extracellular polyamine concentration needed to trigger proliferation, and whether polyamine‑specific mitogenic signalling dominates over other MK‑derived factors (PDGF, TGF‑β).

**Revised directional chain:**  

1. Hypoxia → MK *Amd1* up → spermidine/spermine overproduction.  
2. Polyamines are released (soluble or via microparticles) into the perivascular space.  
3. Proximal PASMCs take up polyamines; intracellular spermidine facilitates eIF5A hypusination (candidate example) or modulates ion channels/growth factor signalling.  
4. Enhanced PASMC proliferation and migration → medial thickening.  
5. Contributes to muscularization and hemodynamic impairment.

**Note on mandatory gene list:** This hypothesis does not rely on the unverified extracellular matrix/coagulation genes.

**Unsupported claims removed:**  

- No longer asserts that the mechanism is independent of immune modulation; acknowledges the difficulty of attributing effects solely to polyamines when multiple MK products are altered.  
- Removed any implication that eIF5A hypusination leads to specific growth‑factor translation (e.g., PDGF‑B) without evidence; kept as a generic candidate.

**Experimental improvement:**  

- *Perturbation:* Conditional *Amd1*‑KO; also employ a polyamine synthesis inhibitor (DFMO) in WT mice.  
- *Model:* Hypoxia + in vitro MK‑PASMC co‑culture using primary lung MKs (from hypoxic mice).  
- *Readout:* PASMC proliferation (EdU/Ki67), spermidine/spermine concentration in co‑culture supernatant and in microdissected vessel wall (LC‑MS), and medial thickness.  
- *Expected result:* *Amd1*‑KO or DFMO reduces polyamine levels and PASMC proliferation; exogenous spermidine restores the mitogenic effect.  
- *Falsifying result:* Polyamine reduction does not alter PASMC proliferation or the effect is not rescued by spermidine; OR *Amd1*‑KO reduces muscularization without changing PASMC proliferation.

**Remaining weaknesses:**  

- Spatial proximity of lung MKs to the medial layer is unproven; without imaging validation the axis remains speculative.  
- Polyamine‑specific receptor/transporter on PASMCs not identified.  

**Recommendation:**  
- **Needs additional evidence** (spatial co‑localization, in‑vitro mitogenicity) before it can be advanced as a primary axis; deprioritize relative to Axis1_AMD1_immune.

---

### Hypothesis ID: Axis1_Inosine_immune  
**Original hypothesis IDs merged:** generation_metabolic‑Axis4_Inosine_immune, generation_2‑Axis2_Pnp_Immune (likely identical), generation_3‑Axis2_Pnp_immune.  
**Revision type:** merge and refine  
**PI feedback addressed:** Candidate‑axis validation for Evo_H2; immune‑mediated direction based on inosine/adenosine.  
**Revised hypothesis title:**  
MK Pnp‑generated inosine/adenosine suppresses perivascular immune surveillance, permitting vascular remodeling.

**Revised core directional hypothesis:**  
Hypoxic MKs upregulate *Pnp* (and *Nt5c2*), resulting in increased inosine release; local conversion to adenosine creates an immunosuppressive perivascular niche that blunts protective anti‑remodeling immunity, allowing unchecked PASMC proliferation and muscularization.

**Revised direction‑level reasoning summary:**  

- *Data anchor:* Inosine elevated in PH‑CD41⁺ MKs (log2FC 3.82, sFig6A); *Pnp* is strongly upregulated in PH MKs (log2FC 1.739, p = 3.81 × 10⁻⁶) despite modest baseline enrichment; *Nt5c2* also upregulated (log2FC 2.879, p = 2 × 10⁻⁴).  
- *Biological interpretation:* Pnp is a direct inosine‑producing enzyme; hypoxia‑induced purine catabolism in MKs provides a local source of inosine that can be extracellularly converted to adenosine (via CD73 on endothelial or other cells). Adenosine is a well‑characterized immunosuppressant acting through A2A/A2B receptors.  
- *MK‑linked pathway logic:* Pnp directly acts on inosine; its PH‑up regulation in MKs indicates a persistent purine release. The adenosine generated can depress effector T‑cell and macrophage responses, disrupting immune‑mediated vascular repair.  
- *Candidate downstream axis:* **Immune‑mediated suppression**. Direct vascular‑wall (adenosine as a mitogen) and stromal (fibroblast activation) are alternative routes.  
- *Remodeling logic:* Without active immune surveillance and beneficial repair signals, stress‑induced signals from endothelial/smooth muscle cells drive unopposed remodeling.  
- *Key uncertainty:* Whether MK‑derived inosine is quantitatively sufficient to shift local adenosine levels, whether CD73 is expressed on cells adjacent to MKs, and whether the net immune effect is pro‑remodeling in the hypoxic lung (adenosine’s effects are context‑dependent).

**Revised directional chain:**  

1. Hypoxia → MK *Pnp*/*Nt5c2* upregulation → elevated inosine production/export.  
2. Inosine is metabolized to adenosine by ecto‑nucleotidases (e.g., CD73) on perivascular cells.  
3. Adenosine binds A2A/A2B receptors on perivascular T‑cells and macrophages, suppressing effector functions (candidate example: reduced IFN‑γ, enhanced IL‑10).  
4. Immune‑mediated vascular repair is impaired; pro‑remodeling signals are unchecked.  
5. PASMC hyperplasia and medial thickening progress.

**Candidate downstream axes:**  

- *Plausible axes:* Immune‑mediated suppression, direct vascular‑wall (adenosine receptor‑mediated proliferation), stromal activation.  
- *Working model (provisional):* Adenosine‑driven T‑cell/macrophage suppression.  
- *Specific examples (candidate only):* A2B receptor on macrophages promoting an immunosuppressive phenotype; A2A on T‑cells blunting effector function. Not settled.  
- *What remains unresolved:* The relative contribution of MK‑derived inosine vs. other sources; which receptor subtype is dominant; the conversion efficiency to adenosine.

**Unsupported claims removed:**  

- Any assumption that A2B receptor blockade alone is sufficient to define the axis.  
- Over‑resolution to a specific cytokine profile (IL‑10 dominance) without tissue validation.

**Experimental validation (improved):**  

- *Perturbation:* MK‑specific *Pnp* knockout (Pf4‑Cre).  
- *Model:* Hypoxic PH mouse; also pharmacological A2B blockade (MRS1754) to disentangle receptor contributions.  
- *Readout:* Lung adenosine concentration (microdialysis), perivascular immune cell activation (flow cytometry for T‑cell/macrophage exhaustion/regulation markers), and muscularization.  
- *Expected result:* *Pnp*‑KO reduces local adenosine, restores effector T‑cell/macrophage function, and attenuates remodeling. A2B blockade partially recapitulates.  
- *Falsifying result:* No change in adenosine or immune composition despite reduced MK inosine; or adenosine receptor antagonism worsens PH (indicating a protective role).

**Remaining weaknesses:**  

- CD73 expression on perivascular cells not confirmed.  
- Inosine‑adenosine conversion may occur away from the perivascular niche, reducing MK‑specific contribution.  
- The immunosuppressive direction may not be the only adenosine effect; A2B on PASMCs could promote proliferation, complicating interpretation.

**Recommendation:**  
- **Ready for PI review** as the leading Evo_H2 candidate axis; however, immediately initiate CD73 expression profiling and tissue adenosine measurement.

---

### Hypothesis ID: Axis2_Inosine_vascular  
**Original hypothesis IDs merged:** generation_metabolic‑Axis5_Inosine_vascular, generation_2‑Axis2_Pnp_Vascular.  
**Revision type:** refine (and downgrade)  
**PI feedback addressed:** Direct vascular‑wall route for inosine; must be explicitly conditional.  
**Revised hypothesis title:**  
MK‑derived inosine supplies purine precursors for PASMC proliferation (conditional on salvage‑pathway limitation).

**Revised core directional hypothesis:**  
If the salvage pathway is rate‑limiting for nucleotide synthesis in hypoxic PASMCs, then MK‑released inosine, taken up via nucleoside transporters and converted to IMP, could directly fuel DNA/ATP synthesis and support medial hyperplasia; adenosine receptor signalling adds a potentially concurrent proliferative stimulus.

**Revised direction‑level reasoning summary:**  

- *Data anchor:* Same inosine‑Pnp axis.  
- *Biological interpretation:* Rapidly dividing cells often rely on pre‑formed nucleosides to supplement de novo synthesis, especially under hypoxia. MK‑derived inosine could theoretically provide a metabolic advantage to adjacent vascular cells.  
- *MK‑linked pathway logic:* Pnp generates inosine; nucleoside transporters on PASMCs enable uptake; intracellular inosine is salvaged to IMP → ATP/DNA. Adenosine A2B receptors may also be stimulated.  
- *Candidate downstream axis:* **Direct vascular‑wall** (metabolic support + adenosine receptor signalling).  
- *Remodeling logic:* Enhanced nucleotide availability promotes PASMC cycle progression and medial hypertrophy.  
- *Key uncertainty:* Whether purine salvage is truly limiting in hypoxic PASMCs; most cells can upregulate de novo synthesis. The hypothesis is highly dependent on conditions where salvage becomes essential.

**Revised directional chain:**  

1. Hypoxic MKs release inosine.  
2. Inosine is transported into PASMCs via equilibrative nucleoside transporters (ENT1/2).  
3. Inosine is phosphorylated to IMP and used for ATP/DNA synthesis; simultaneously, intracellular adenosine derived from inosine activates A2B receptors.  
4. Enhanced nucleotide supply and receptor signalling synergize to drive PASMC proliferation.  
5. Medial thickening and increased resistance.

**Unsupported claims removed:**  

- Removed any assertion that inosine salvage is the dominant mechanism; now explicitly conditional and presented as a low‑confidence secondary axis.

**Added evidence gap statement:**  

- **Mandatory whole‑lung metabolomics cross‑check**: methionine, inosine, and spermidine/spermine levels in whole‑lung homogenate were not extracted from `Figure6D+F raw data.xlsx`. Knowing whether tissue inosine is elevated would help gauge substrate availability.
- **No isotope‑tracing data** exists to demonstrate that MK‑derived inosine is incorporated into PASMC nucleotides.

**Experimental validation (conditional):**  

- *Perturbation:* MK‑specific *Pnp*‑KO + stable‑isotope‑labelled inosine infusion.  
- *Model:* Hypoxic mouse; PASMC nucleotide extraction and LC‑MS.  
- *Readout:* ¹³C‑inosine incorporation into PASMC IMP/ATP, PASMC proliferation, and muscularization.  
- *Expected result:* KO reduces incorporation and proliferation, rescued by exogenous inosine.  
- *Falsifying result:* No change in incorporation or proliferation; salvage not rate‑limiting.

**Recommendation:**  
- **Should be deprioritized** until salvage‑pathway necessity is demonstrated; retain only as a long‑shot secondary hypothesis.

---

## Summary of rejected/deprioritized axes

- **AMD1‑polyamine EV/stromal** – removed; EV‑biogenesis gene expression unverified, polyamine‑EV loading unproven.  
- **Inosine‑adenosine stromal activation** – removed; no direct fibroblast‑A2B data in PH context.  
- **AMD1‑thrombo‑inflammatory** – removed; relies on unverified F3/Thbs1 expression and speculative eIF5A‑dependent translation.  
- **Matricellular/coagulation/EV secretome** – removed; mandatory Seurat gene list not independently verified, no metabolite‑enzyme anchor; cannot be advanced without completed Tool Use Agent queries.

---

## Overarching evidence gaps that affect all refined hypotheses

1. **Mandatory Seurat expression checks** for *Pdgfb, Tgfb1, F3, Thbs1, Glo1, Rab27a, Tsg101, Cd44, Lox, Loxl1, Loxl2, Mki67* have only been self‑reported by generation agents – **not verified** by the Tool Use Agent. This prevents any hypothesis that incorporates these genes from being considered anchored.  
2. **GSE289322 DE and GSEA results** are completed but not displayed; tissue‑level pathway enrichment (for arginine/proline metabolism, purine metabolism, coagulation, TGF‑β, ECM) cannot be assessed.  
3. **Whole‑lung metabolomics cross‑check** was not performed; methionine, inosine, and spermidine/spermine levels in whole‑lung tissue are unknown.  
4. **Spermidine/spermine** themselves were not measured in MK‑sorted metabolomics, leaving the AMD1‑polyamine flux inference without direct product confirmation.  
5. **Spatial relationship** of lung MKs to the vascular media, perivascular immune cells, and fibroblasts remains undetermined, limiting all direct‑interaction claims.

---

**The next cycle must begin with the Tool Use Agent delivering these missing data; only then can the refined hypotheses be fully evaluated and the TSP‑1/TGF‑β secretome axis be reconsidered if data meet the threshold.**
